Benchmark began coverage on shares of Kamada (NASDAQ:KMDA - Get Free Report) in a research report issued on Friday, MarketBeat.com reports. The brokerage set a "buy" rating and a $15.00 price target on the biotechnology company's stock. Benchmark's price objective suggests a potential upside of 111.86% from the company's previous close.
Several other brokerages also recently issued reports on KMDA. StockNews.com upgraded Kamada from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 13th. HC Wainwright reissued a "buy" rating and set a $11.00 price objective on shares of Kamada in a report on Thursday, March 6th.
View Our Latest Report on KMDA
Kamada Trading Down 0.3 %
KMDA stock traded down $0.02 during trading on Friday, hitting $7.08. The company had a trading volume of 61,393 shares, compared to its average volume of 78,691. The company has a market cap of $406.96 million, a P/E ratio of 25.29, a P/E/G ratio of 0.97 and a beta of 0.97. The company has a fifty day moving average price of $7.19 and a two-hundred day moving average price of $6.28. Kamada has a fifty-two week low of $4.74 and a fifty-two week high of $9.16.
Institutional Trading of Kamada
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after purchasing an additional 1,549 shares during the last quarter. Aristides Capital LLC grew its holdings in Kamada by 12.1% during the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after acquiring an additional 6,850 shares during the period. NewEdge Advisors LLC raised its position in shares of Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after acquiring an additional 8,260 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Kamada in the 4th quarter valued at $67,000. Finally, Public Employees Retirement System of Ohio bought a new position in shares of Kamada in the 3rd quarter worth $77,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.
About Kamada
(
Get Free Report)
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.
See Also
Before you consider Kamada, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kamada wasn't on the list.
While Kamada currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
